
Olcay Y Jones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4777406/publications.pdf Version: 2024-02-01



OLCAY Y LONES

#	Article	IF	CITATIONS
1	Is Long COVID a State of Systemic Pericyte Disarray?. Journal of Clinical Medicine, 2022, 11, 572.	1.0	5
2	Intrarenal injection of mesenchymal stem cell for treatment of lupus nephritis in mice – a pilot study. Lupus, 2021, 30, 52-60.	0.8	5
3	Multisystem Inflammatory Syndrome in Children during the COVID-19 Pandemic: A Case Report on Managing the Hyperinflammation. Military Medicine, 2021, 186, e270-e276.	0.4	9
4	Sixteen Weeks Later: Expanding the Risk Period for Multisystem Inflammatory Syndrome in Children. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 686-690.	0.6	23
5	Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series. Pediatric Rheumatology, 2021, 19, 87.	0.9	7
6	Long-term outcomes in Juvenile Myositis patients. Seminars in Arthritis and Rheumatism, 2020, 50, 149-155.	1.6	21
7	Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open, 2020, 6, e001208.	1.8	13
8	Common genetic susceptibility loci link PFAPA syndrome, Behçet's disease, and recurrent aphthous stomatitis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14405-14411.	3.3	52
9	Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis—A Critical Review of Its Pathogenesis and Treatment. Frontiers in Pediatrics, 2020, 8, 626182.	0.9	120
10	Fashionably Late: A Case of Delayed Cutaneous Manifestations in Juvenile Dermatomyositis. Journal of Clinical Medicine Research, 2018, 10, 848-852.	0.6	3
11	Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology, 2017, 56, 1342-1347.	0.9	46
12	Cell-based treatment of renal dysfunction. Stem Cell Fundamentals and Practice, 2015, 1, 23.	0.0	0
13	A125: Immunomodulatory Factors Produced by Mesenchymal Stem Cells Afterin vitroPriming with Danger Signals. Arthritis and Rheumatology, 2014, 66, S163-S163.	2.9	3
14	A112: Prevention of Late Stage Renal Failure in BXSB SLE Mouse Model with Human Bone Marrow Derived Mesenchymal Stem Cell Treatment. Arthritis and Rheumatology, 2014, 66, S149-S149.	2.9	3
15	Activated STING in a Vascular and Pulmonary Syndrome. New England Journal of Medicine, 2014, 371, 507-518.	13.9	1,074
16	Developments in the Classification and Treatment of the Juvenile Idiopathic Inflammatory Myopathies. Rheumatic Disease Clinics of North America, 2013, 39, 877-904.	0.8	74
17	Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy. Arthritis Care and Research, 2013, 65, 1969-1975.	1.5	21
18	Recent advances in the management of children with familial Mediterranean fever. International Journal of Clinical Rheumatology, 2013, 8, 233-245.	0.3	3

Olcay Y Jones

#	Article	IF	CITATIONS
19	Successful Treatment of Pansclerotic Morphea with Imatinib Mesylate in a Pediatric Patient. Annals of Paediatric Rheumatology, 2013, 2, 43.	0.0	3
20	Hyper IgD Syndrome Presenting as Sweet's Syndrome in a 6 week old Infant. Annals of Paediatric Rheumatology, 2013, 2, 118.	0.0	0
21	Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and Calcinosis. Journal of Pediatrics, 2012, 160, 520-522.	0.9	99
22	Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care and Research, 2012, 64, 375-383.	1.5	164
23	Where is the Heart of Immune Regulation?. Annals of Paediatric Rheumatology, 2012, 1, 81.	0.0	0
24	Regeneration, a Tale of Two Mice. Annals of Paediatric Rheumatology, 2012, 1, 205.	0.0	0
25	Engraftment of donor mesenchymal stem cells in chimeric BXSB includes vascular endothelial cells and hepatocytes. Stem Cells and Cloning: Advances and Applications, 2011, 4, 73.	2.3	2
26	Parents' perception of self-advocacy of children with myositis: an anonymous online survey. Pediatric Rheumatology, 2011, 9, 10.	0.9	8
27	Long-term follow-up after non-myeloablative transplant of bone and marrow in BXSB mice. Lupus, 2009, 18, 813-821.	0.8	4
28	RENAL PATHOLOGY AND MORPHOMETRIC STUDIES ON NATURAL HISTORY OF BXSB LUPUS MICE. FASEB Journal, 2009, 23, 1004.2.	0.2	0
29	Nonmyeloablative allogeneic bone marrow transplantation of a child with systemic autoimmune disease and lung vasculitis. Immunologic Research, 2008, 41, 26-33.	1.3	3
30	Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1987-1994.	6.7	166
31	Comparison of treatment-response criteria for juvenile idiopathic arthritis. Nature Clinical Practice Rheumatology, 2006, 2, 466-467.	3.2	0
32	A Multicenter Case-Control Study on Predictive Factors Distinguishing Childhood Leukemia From Juvenile Rheumatoid Arthritis. Pediatrics, 2006, 117, e840-e844.	1.0	125
33	Nonmyeloablative Bone Marrow Transplantation of BXSB Lupus Mice Using Fully Matched Allogeneic Donor Cells from Green Fluorescent Protein Transgenic Mice. Journal of Immunology, 2004, 172, 5415-5419.	0.4	20